Get started

Biotech

"NBIX Stock Breaks All-Time Highs, Strong Buy Opportunity!"NBIX Stock Breaks All-Time Highs: A Strong Buy Opportunity Emerges Neurocrine Biosciences Inc. (NBIX) is currently making waves in the stock market as it breaks out of its all-time highs, signaling a promising opportunity for investors. After 14 years of steady upward momentum and price consolidation, NBIX appears poised for further growth, with technical indicators suggesting a bullish trend ahead. The recent surge in NBIX's stock price comes on the heels of strong performance and positive sentiment surrounding the company's products and pipeline. With a focus on innovative treatments for neurological and endocrine disorders, Neurocrine Biosciences has established itself as a leader in the biopharmaceutical industry, attracting investors seeking exposure to high-growth sectors. Technical analysis reveals that NBIX's current breakout is accompanied by the formation of a bull flag pattern, a bullish continuation pattern that often precedes further upward movement. This consolidation phase following a prolonged uptrend suggests that NBIX may be gearing up for another leg higher, providing an attractive entry point for investors. To capitalize on this potential opportunity, traders are advised to monitor the 4-hour time frame closely, watching for confirmation of the breakout and additional upside momentum. A sustained move above the current resistance levels could signal further strength in NBIX's stock price, potentially leading to a retest of its previous all-time highs. Investors considering a position in NBIX should also keep an eye on key support levels and market dynamics, as volatility in the broader market could impact the stock's trajectory. However, with a strong track record of growth and a robust pipeline of innovative therapies, NBIX appears well-positioned to weather any short-term fluctuations and deliver long-term value to shareholders. In conclusion, Neurocrine Biosciences Inc. is breaking out of its all-time highs, presenting a compelling buying opportunity for investors. With 14 years of upward momentum behind it and a bullish pattern forming, NBIX looks poised for further growth in the coming weeks and months. By monitoring the 4-hour time frame and remaining vigilant for additional breakouts, investors can position themselves to capitalize on the potential upside in NBIX's stock price.
NASDAQ:NBIXLong
by UnknownUnicorn2319099
MGNX a biotech company gets new "Outperform" LONGMGNX as a biotech company makes antibodies against certain cancers. The antibody is tagged to chemotherapy molecules and then heads off looking for cancer cells to which it has a strong affinity. So much for the science. MGNX just got upgraded and the new target is $ 16.00 about 25% upside. Biotech and healthcare are projected hot sectors this year. On the 15 minute chart price jumped about 12% in the past week and bounced down toward the anchored mean VWAP and is well situated for a long entry. the dual TF RSI indicator shows both lines crossing the 50 level in early bullish momentum off the bounce. It is continually hitting new past year highs at a great trend angle and is on pace to hit 400% for an annual return. There is no option play here as the volume is minimal and liquidity is absent. The all-time high is about $32 so there is plenty of room above the analyst's target over the long term. Price has moved 12X the S & P YTD certainly a sign of relative strength.
NASDAQ:MGNXLong
by AwesomeAvani
1
Bluebird Bio (NASDAQ: BLUE) Posing Strong Bearish TrendBLUE is currently trading above its 50-day and 200-day simple moving averages (SMA), indicating a bullish trend. However, the 50-day SMA is below the 200-day SMA, forming a death cross pattern, which is a bearish signal. The 20-day exponential moving average (EMA) is also above the current price, acting as a resistance level. A break above the 20-day EMA could signal a continuation of the uptrend, while a break below the 50-day SMA could signal a reversal of the trend. Earnings and Revenue: The earnings per share (EPS) of BLUE is expected to decline by 37.50% in the current quarter (Dec 2023) and increase by 333.30% in the next quarter (Mar 2024). The EPS for the current year (2023) is estimated to be -$11.7, which is a 59.10% decrease from the previous year (2022). The EPS for the next year (2024) is projected to be -$8.6, which is an 26.50% increase from the current year2. The revenue of BLUE is expected to decrease by 3.10% in the current quarter (Dec 2023) and increase by 9.00% in the next quarter (Mar 2024). The revenue for the current year (2023) is estimated to be $289.2 million, which is a 0.80% decrease from the previous year (2022). The revenue for the next year (2024) is forecasted to be $313.6 million, which is a 8.40% increase from the current year. The technical analysis of BLUE shows that the stock is in a mixed trend, with some bullish and bearish signals. The stock is also facing low volatility and uncertain momentum. The earnings and revenue estimates suggest that the company is going through a challenging period, but might recover in the future.
NASDAQ:BLUEShort
by DEXWireNews
SRPT Sarepta Therapeutics Potential Buyout SoonIf you haven`t bought SRPT here: Then you need to know that there is a Massive catalyst coming! Sarepta Therapeutics is going to announce Duchenne muscular dystrophy Phase 3 data for its SRP-9001-301 - (EMBARK) by mid November. This week institutions bought calls worth more than $10Mil that SRPT Sarepta Therapeutics will trade above $135 by November 17. Some even bought the $210 strike price! They also have a big partnership with the giant Roche Holding AG (RHHBY). I think SRPT Sarepta Therapeutics is well positioned for a potential takeover soon! Looking forward to read your opinion about it.
NASDAQ:SRPTLong
by TopgOptions
NVTA Invitae Corporation All Time Low | Potential Buyout !Last year in Autumn we had this buyout rumor. I remember back then Exact Sciences said to approach Invitae about a potential merger. Now, NVTA, Invitae Corporation, is trading at an all-time low, $0.62. Some deals take one or two years to perfect, and we don't know what caused the recent price decrease. Sometimes this happens before an announcement. Today, Invitae announced the appointment of finance veteran Ana Schrank as CFO; she spent more than 20 years at McKesson Corporation where she held leadership roles. Could this CFO be hired ahead of a takeover?! We don't know! But with an RSI of 19.34 and an all-time low, along with ARK Invest being the 2nd largest shareholder at an average price of $15.08, I think this looks like a great buying opportunity! Looking forward to read your opinion about it!
NLong
by TopgOptions
2
GRI Bio periodic pumps GRI Bio recently underwent a 1/30 split on April 24th, accompanied by a merger/restructure of Vallon Pharmaceuticals. The stock price immediately tanked approx. 50% in the following days. The price has held above the low of $5.50 on April 26th for over a month. Based on past performance, this stock has a tendency to jump 30 to >200% in a single day. GRI Bio has touted the merger and restructuring will bring "near term" value to stock holders, and perhaps a catalyst will emerge in the coming month(s). I think this is a safe long with stops at $5.50 or thereabouts. A jump to $10 or higher seems reasonable, but will likely retrace immediately.
NASDAQ:GRILong
by nothximgood
1
ETON Biotech Big Earning Beat Pullback LONGETON jumped on a big earnings report a week ago. This small cap biotechology company is making big money and traders responded. It has now experienced a standard 0.5 Fib level retracement pullback and traders early in the jump take profit. At this level new buyers have equilibrated with those selling their shares and taking profit. The ZL MACD lines are ready to cross bearly under the histogram whose negative/ red amplitude is reverting toward the zero line. The lines of the dual time frame RS indicator have held above the 50 level. In consideration of this healthy pullback and buying /selling pressure equilibrium I will take a long trade looking for 15-20% upside considering also the uprising fundamentals of the stock based on the big earnings beat.
NASDAQ:ETONLong
by AwesomeAvani
8
NKTR High Tight Flag- Pre-Earnings High Flyer LONGNKTR is due for earnings on August 8th. The price from the opening bell on the 7th pump nearly 100% to over $1.00 and then faded by a couple of cents. The Price Momentum Oscillator and ZL MACD indicators tracked the high velocity action into a high tight type bull falg which is often considered to be predictive of another leg up of similar magnitude. I will be watching this in the premarket upcoming and also at the report of earnings. I hope to catch a decent ride. If I do get it I will quit the ride as soon as the indicators flip signals. This could be a good one. Buyer anticipation and sentiment could yield great profit in little time the money is exposed to the market.
NASDAQ:NKTRLong
by AwesomeAvani
3
QSI Quantum-Si Earnings Release on Monday, Before the BellIf you haven`t bought the Double Bottom: Then you should know that QSI, Quantum-Si incorporated, also known as The Protein Sequencing Company is bringing single-molecule protein sequencing to every lab, everywhere, enabling new discoveries that will transform the world we live in. Importance of Protein Sequencing: - Understanding Cellular Processes: Proteins are involved in virtually every cellular process, and their sequencing is vital for understanding how these processes are regulated and how dysfunction leads to diseases. - Drug Development: Protein sequencing assists in drug discovery by identifying specific targets for pharmaceutical intervention. This knowledge enables the design of drugs that can interact with specific proteins, thereby treating diseases more effectively. - Bioengineering and Enzyme Production: Protein sequencing is critical in the field of bioengineering, allowing the design of proteins with tailored functions for various applications, including industrial enzyme production and bioremediation. I think protein sequencing should have the same importance as gene sequencing. Gene sequencing has revolutionized medical research, agriculture, and our comprehension of evolutionary history. On the other hand, protein sequencing has paved the way for targeted drug development, bioengineering, and the investigation of cellular processes. QSI has cash and cash equivalents of $322.1 million as of March 31,2023 to provide a runway to support operations and invest in the business into 2026, and NO debt! This Quarter started he sale of PlatinumTM instruments and kits with a gross margin of 48.8%. QSI has a Market Cap of $485Mil vs CRSP, my favorite gene editing company, with a Market Cap of 4.046Bil. So there is still a lot of upside in QSI Quantum-Si incorporated! Looking forward to read your opinion about it.
NASDAQ:QSILong
by TopgOptions
ZYXI reverses from whipsaw volatility LONGXYNI is now ready to reverse long. I analyze this because ZYXI has dropped from overvalued and overbought through the fair value zone into undervalued territory in three trading days by viewing the anchored VWAP bands and the volume profile, The mean VWAP and POC line are confluent at 7.25. This is the logical first target. The MACD lines are negative 4X the amplitude of the the negative histogram on the 2H and impending cross. The mass index is a sensitive signal of reversal potential is about to trigger and probably has done so on lower time frames. I will take ZYXI long with a good entry to be found on a 15-30 minute the time frame when I get an alert that it has crossed over the hand-drawn resistance trend line. I am expecting 8% before the first take profit target and 12% on the overall trade over the next 5 trading days or so. A modest profit for low risk, I think. Anyone in faraway places from the Wall Street market manipulators and FDA, this one is for you.
NASDAQ:ZYXILong
by AwesomeAvani
4
CRSP: Big orrection after the next rally, but buy-the-dip.I believe that CRSP (Crispr Therapeutics) is about to undergo a severe correction soon. I scaled into this stock during the latter part of 2022 and the first part of 2023 and it is up nearly 70% and has generated about 40% of pure alpha for me relative to the SPX. So this has been an amazing performer for my total portfolio. I believe this run may be nearing a pullback and I expect the correction to be a very severe one. My suggestion is that this will form a triple-bottom/inverse head-and-shoulders pattern because this will be a subwave 2 correction and in theory, it should not overthrow the recent low by very much. I think the post-correction rally will be sizeable (it'll be a macro Wave 3) and the catalyst for this rally will be the steady trend of slowly improving earnings that they have demonstrated over the past year. (3 successive quarters of positive earnings calls - this has not been achieved since 2017) So, in essence, presuming nothing else changes, I believe we should buy the next dip for a significant Wave 3 rally that will exceed the all-time highs. In the meantime, expect lots of volatility, if you don't have the stomach for taking drawdowns or losses in the interim, you may want to sell the next rally so that you can buy back in. I will probably pursue this course of action myself purely as a matter of greed to preserve the alpha I have managed to capture. Happy biotech trading!
NASDAQ:CRSPLong
by RogueEconomics
FLMD biotechology rising post earningsFLMD had earnings in May with positive earnings beating the expectation of analysts that it would continue to lose quarter after quarter. Investors and traders have reacted with a 80% run-up in the month after those earnings. On the 30-minute chart besides the consistent uptrend with minor corrections, what stands out for me is the increasing volumes relative to volumes before the last earnings report. Off the chart, I find information that insider trading with buying more shares on top of existing holdings leads me to believe that this company expects increasing revenues and sustained earnings.
NASDAQ:LFMDLong
by AwesomeAvani
AUTL Is this a pump and dump?AUTL on the one-hour chart had a spontaneous parabolic move without a catalyst as best as I can tell. Earnings ten days ago were decent but nothing special. AUTL as a biotech firm is losing cash just not as much as analysts predicted. In the parabolic move very few shares were traded between $2.00 and $2.40 as per the volume profile Overall a massive volume occurred compared with the entire year although there was a bit in the runup to earnings. I suspect a pump and dump and think it might be worth playing. Insiders could be manipulating the shares and acting as a team. The zero-lag MACD suggests that the top has been reached. I believe that insiders will be selling quickly and short sellers will be joining in. I will be one of the latter. Retail buyers could be stuck bag holding if caught by surprise. Once price drops to $4.00 the bearish momentum will kick in due to the volume void on the profile. Accordingly, I will buy a group of call options when AUTL hits $4.05 set a stop loss and await the flush back down to $2.00. If things go well this will be over a 100% return on investment and 300% return on risk in one day. The contracts for 6/16 ( $5.00) are about $250 with about 25% spread between the bid and ask.
NASDAQ:AUTLShort
by AwesomeAvani
Pullback Buy in TGTXBiotech stocks can make huge moves, and this one is no exception. TGTX more than doubled in a month and is showing no signs of slowing down. Slower-trending, blue chip stocks tend to ride their 50-day moving average (red line on chart) on the way up. Stronger stocks tend to hold their 21-day moving average (blue line). But with high-flying honey badger stocks like TGTX, you are lucky to get a pullback to the 10-day (yellow line). TGTX touched its 10-day exponential moving average on Friday, making this the first real pullback buying opportunity since the initial surge. I would consider buying here with an 8-10% stop loss.
NASDAQ:TGTXLong
by rossgivens
VYNE Biotech Post Earnings VYNE had a favorable earnings report last week. Fundamentally, analysts predict ( linked) approximately a doubling of the shart price in the next year. Like many low share priced biotechnology stocks the price is based on perceived future earnings which can be affected by favorable FDA process, or well-received research at industry conferences and changing financials within the company. In general, they have a low beta meaning these stocks are not general market responsive and run on their own present or future merits. On the 15-minute chart VYNE was trending down into earnings and the pivoted with a reversal into the present. The Luxalgo AI "Echo indicator" predicts an upside of 20% in the next two days before a consolidation period. The "Trendflex" indicator has flipped to postiive and green. I will take this long trade with a stop loss of $0.15 per share and target of $9.00 over two days for a 20% ROI and a R:R of 0.15 risk / $ 1.50 reward for a 10:1> Iwill only take biotechology trades long with a high R:R due to the inheret risk level.
NASDAQ:VYNE
by AwesomeAvani